PharmiNews

The Directory of Pharma Companies and News

Oxford Biomedica

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company’s technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.
Category:
Category:

Oxford Biomedica News

DateNews
2017-02-28Appointment of New Chief Financial Officer
2017-02-24Oxford BioMedica Notes Encouraging Results of the Investigator Led Phase I/II clinical trial of MVA-5T4 Immunotherapy (T...
2016-12-05Oxford BioMedica Notes Findings Reported by Novartis on CTL-019 at 58th American Society of Hematology Annual Meeting
2016-11-29Oxford BioMedica Announces a Strategic Alliance with Orchard Therapeutics
2016-10-10Oxford BioMedica Announces Publication of Pioneering RetinoStat® (OXB-201) Phase I Study Data in the Journal, Human Gene...
2016-09-29Oxford BioMedica Result of General Meeting and Directors Dealing
2016-09-13Proposed fundraising of £10 million by way of a placing, subscription and related party transaction
2016-09-13Interim Results for the six months ended 30 June 2016
2016-09-13Oxford BioMedica Interim Results Replay
2016-07-28Oxford BioMedica Announces MHRA GMP Manufacturing Approvals and Completion of Expansion Phase
2016-06-07Establishment of a New Non-Exclusive LentiVector® Licence with MolMed
2016-06-07Oxford BioMedica to Present at the Jefferies 2016 Healthcare Conference, New York
2016-06-02Oxford BioMedica and Green Cross LabCell form a Partnership to Develop Gene-modified NK Cell Therapeutics in cancer
2016-05-17Oxford BioMedica Appoints Corporate Broker
2016-05-12Oxford BioMedica Board Change
2016-05-06Oxford BioMedica Presents Ground-Breaking Evidence of Long-Term Duration of Therapeutic Expression in Patients from its ...
2016-04-28Oxford BioMedica Preliminary Results Replay
2016-04-28OXFORD BIOMEDICA: PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2015
2016-04-26Oxford BioMedica Announces Stuart Henderson Appointed as a Non-Executive Director
2016-03-07Oxford BioMedica Announces Expanded Collaboration and Licence with Immune Design
2016-02-23Oxford BioMedica announces a proposed placing to raise £8.1 Million
2016-01-29Oxford BioMedica Announces Initiation of Second CART Programme for Major Pharmaceutical Company
2016-01-13Oxford BioMedica Announces Successful MHRA Inspection and Approval to Manufacture at its new Facility in Yarnton, Oxford
2016-01-05Board change
2015-12-15Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, is pleased t...
2015-11-18Oxford BioMedica to present at the Jefferies 2015 Global Healthcare Conference, London
2015-11-09Alex's Test
2015-11-04Business Update
2015-10-28GSK Exercises Option on Oxford BioMedica’s LentiVector® Technology Patents
2015-08-27INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2015
2015-08-06Oxford BioMedica: Notice of Interim Results Results date: 27 August 2015
2015-06-23Oxford BioMedica to present at JMP Securities Life Sciences Conference 2015 in New York and to attend ROTH Healthcare Da...
2015-05-29Oxford BioMedica to Present at Jefferies 2015 Global Healthcare Conference, New York
2015-05-13Oxford BioMedica Appoints Daniel Soland as Non-Executive Director to the Board
2015-05-05Oxford BioMedica’s Phase I study results with RetinoStat® were selected as a “Hot Topic” at the Association for Research...
2015-05-05Oxford BioMedica announces that a summary of the 12 month and three year follow up data from the Phase I/II study with P...
2015-05-01Oxford BioMedica secures $50 million loan facility with Oberland Capital to support the Group's growth ambitions
2015-04-02Oxford BioMedica 2014 Annual Report and Accounts & AGM Notification
2015-03-23Oxford BioMedica to Present at 3rd Annual Regen Med Investor Day
2015-03-162014 Preliminary Results Replay
2015-03-13Oxford BioMedica: Preliminary results for the year ended 31 December 2014
2015-03-06Oxford BioMedica: Notice of Preliminary Results
2015-03-05Oxford BioMedica Announces Presentation at 27th Annual ROTH Conference
2015-03-03Oxford BioMedica to Participate in Credit Suisse’s Global Healthcare One-on-One Conference
2015-02-23Chief Secretary to the Treasury visits Oxford BioMedica
2015-01-13John Dawson, Chief Executive Officer, presented at Biotech Showcase™ 2015 Conference in San Francisco, on Monday, 12 Jan...
2014-11-03Oxford BioMedica Interim Management Statement
2014-10-13Oxford BioMedica Acquires Windrush Court Office and Laboratory Facilities
2014-10-10Oxford BioMedica announces new process development and manufacturing collaboration which includes LentiVector® licence a...
2014-08-28INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2014
2014-08-15Oxford BioMedica plc Directorate change
2014-06-20Oxford BioMedica to participate at the Piper Jaffray GenomeRx Symposium in New York on 23 June 2014
2014-06-18Loan Repayment in Full
2014-06-16Result Of General Meeting And Directors Dealing
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.